TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23257490
Drug: Placebo (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (placebo tablet twice a day)
Study: 20967981
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (1 intramuscular injection)
Study: 20967981
Drug: Vardenafil (on-demand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil (on-demand monotherapy for 6 weeks)
Study: 20967981
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (testosterone undecanoate and vardenafil in the same doses and duration)
Study: 15857093
Drug: Implants in
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants in patients with generalized aggressive periodontitis (GAgP)
Study: 15857093
Drug: Implants in
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants in patients with generalized chronic periodontitis (GCP)
Study: 15857093
Drug: Implants in
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants in periodontally healthy patients
Study: 15857093
Drug: Teeth and
Normalized name: SODIUM FLUORIDE 1.1 mg in 1 g DENTAL PASTE, DENTIFRICE [Toms Teeth and Gum Health]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teeth and implants in patients with generalized aggressive periodontitis (GAgP)
Study: 15857093
Drug: Teeth and
Normalized name: SODIUM FLUORIDE 1.1 mg in 1 g DENTAL PASTE, DENTIFRICE [Toms Teeth and Gum Health]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teeth and implants in patients with generalized chronic periodontitis (GCP)
Study: 15857093
Drug: Teeth and
Normalized name: SODIUM FLUORIDE 1.1 mg in 1 g DENTAL PASTE, DENTIFRICE [Toms Teeth and Gum Health]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teeth and implants in periodontally healthy patients
Study: 12055814
Drug: Mebendazole 500
Normalized name: mebendazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole 500 mg
Study: 19769793
Drug: Haplotype comprising
Normalized name: Synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue
DrugBank: CHF5633 (DB18696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haplotype comprising alleles rs659366-G, rs653529-A, rs15763-G and rs1726745-A
Study: 19769793
Drug: Haplotype comprising
Normalized name: Synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue
DrugBank: CHF5633 (DB18696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haplotype comprising alleles rs3781907-G, rs11235972-A, and rs1800849-T
Study: 15675259
Drug: Intranasal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal sufentanil 20 microg and intranasal midazolam 0.3 mg/kg
Study: 15675259
Drug: Intranasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine 5 mg/kg and intranasal midazolam 0.3 mg/kg
Study: 12495409
Drug: High-voltage pulsed
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-voltage pulsed current (HVPC) (100 microseconds, 150 V, 100 Hz) for 45 minutes, 3 times weekly, for 4 weeks
Study: 12495409
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment for 45 minutes, 3 times weekly, for 4 weeks
Study: 1718692
Drug: Gallopamil 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil 0.4 mg
Study: 29369348
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (800 mg)
Study: 29369348
Drug: Carbamazepine-CR (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine-CR (200 mg BID)
Study: 29369348
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (1200 mg)
Study: 29369348
Drug: Carbamazepine-CR (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine-CR (400 mg BID)
Study: 23364045
Drug: Oral Function
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Function Improvement Exercises (3 times a week for a total of 24 times)
Study: 19939369
Drug: Combined sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined sequential acidic and less‐acidic FSH
Study: 15332095
Drug: Activated device
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated device (meibomian therapy with latent heat)
Study: 8132436
Drug: Paroxetine (20-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20-30 mg daily)
Study: 8132436
Drug: Sulpiride (200-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (200-400 mg daily)
Study: 30711649
Drug: Pembrolizumab 2
Normalized name: pembrolizumab 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 2 or 10 mg/kg every 3 weeks
Study: 29142982
Drug: Etelcalcetide 5
Normalized name: etelcalcetide 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etelcalcetide 5 mg
Study: 29142982
Drug: Etelcalcetide 10
Normalized name: etelcalcetide 10 MG per 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etelcalcetide 10 mg
Study: 29142982
Drug: Etelcalcetide 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etelcalcetide 20 mg
Study: 29142982
Drug: Etelcalcetide 2.5
Normalized name: ETELCALCETIDE 2.5MG/0.5ML INJ,SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etelcalcetide 2.5 mg (multiple dose)
Study: 29142982
Drug: Etelcalcetide 5
Normalized name: etelcalcetide 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etelcalcetide 5 mg (multiple dose)
Study: 29142982
Drug: Etelcalcetide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etelcalcetide (all doses)
Study: 21490520
Drug: Circumferential injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circumferential injection of local anesthetic (30 mL admixture of 1:1 lidocaine 2%/bupivacaine 0.5% with 1:200,000 epinephrine)
Study: 21490520
Drug: Single-location injection
Normalized name: Potassium cation
DrugBank: Potassium cation (DB01345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-location injection of local anesthetic (30 mL admixture of 1:1 lidocaine 2%/bupivacaine 0.5% with 1:200,000 epinephrine)
Study: 11014136
Drug: Evidence-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based treatment recommendations for bite wounds
Study: 9358138
Drug: Low-dose inhaled
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose inhaled budesonide (400 microg) plus theophylline (250 or 375 mg depending on body weight)
Study: 9358138
Drug: High-dose inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inhaled budesonide (800 microg)
Study: 9358138
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (low-dose budesonide plus theophylline and high-dose budesonide)
Study: 8199605
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of zinc gluconate daily
Study: 30458930
Drug: ME-401 10
Normalized name: LIMOSILACTOBACILLUS FERMENTUM ME-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ME-401 10 mg
Study: 30458930
Drug: ME-401 60
Normalized name: LIMOSILACTOBACILLUS FERMENTUM ME-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ME-401 60 mg
Study: 30458930
Drug: ME-401 150
Normalized name: LIMOSILACTOBACILLUS FERMENTUM ME-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ME-401 150 mg
Study: 30458930
Drug: ME-401 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: ME-401 (various doses)
Study: 30458930
Drug: ME-401 once
Normalized name: LIMOSILACTOBACILLUS FERMENTUM ME-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ME-401 once daily 60 mg
Study: 28190787
Drug: Riociguat up
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riociguat up to 2.5 mg 3 times a day
Study: 19538718
Drug: Combination Disease
Normalized name: LYME DISEASE VACCINE
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Disease Modifying Antirheumatic Drug therapy
Study: 19538718
Drug: Monotherapy methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Monotherapy methotrexate
Study: 19538718
Drug: Disease Modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease Modifying Antirheumatic Drug of various intensities
Study: 19538718
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drugs, hydroxychloroquine, and a single dose of corticosteroids
Study: 16951642
Drug: Structured treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured treatment interruption (STI) for 4 months
Study: 11776481
Drug: Acetaminophen 1000
Normalized name: acetaminophen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1000 mg, 4 times daily for 2 consecutive days
Study: 8496384
Drug: Computerised systems
Normalized name: Synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue
DrugBank: CHF5633 (DB18696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerised systems for warfarin control
Study: 8496384
Drug: Computerised dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerised dosage programs
Study: 8496384
Drug: Traditional dosing
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional dosing method by experienced medical staff
Study: 24880749
Drug: Lithium (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (500 mg, twice a day)
Study: 15596954
Drug: Rhythm control
Normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythm control using antiarrhythmic drugs
Study: 12527962
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (OC) users during days 15-28
Study: 12527962
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (OC) users during days 1-14
Study: 8750478
Drug: Intravenous multidrug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous multidrug chemotherapy
Study: 27780197
Drug: Any dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any dose of dextrose gel
Study: 27565734
Drug: 1800 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 mg/day of eicosapentaenoic acid (EPA), n = 53
Study: 24953916
Drug: Bupivacaine moistened
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine moistened dressing (12 mL/100 cm2 of 0.25% bupivacaine solution)
Study: 23297552
Drug: Series of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Series of formulas changed daily according to TCM syndrome
Study: 8970500
Drug: Lithium, starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium, starting at 15 mg/kg of body weight, dosage increase every 3 to 4 days until response or serum level of 1.2 to 1.4 mEq/L
Study: 8970500
Drug: Valproate (divalproex),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valproate (divalproex), initiated at 20 mg/kg of body weight
Study: 8970500
Drug: Carbamazepine, starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine, starting at 200 mg once or twice daily with slow dosage escalation
Study: 1713269
Drug: murine monoclonal
Normalized name: 131I-BC8 monoclonal antibody (Anti-CD45 murine monoclonal antibody radiolabeled with 131I
DrugBank: Apamistamab iodine I-131 (DB16748)
Approvals — FDA: no, EMA: no, PMDA: no
Description: murine monoclonal anti‐CD4 (B‐F5) antibody (10 mg/day, 15 mg/day, 20 mg/day) for 10 consecutive days
Study: 6711781
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release morphine sulphate tablets (MST, 20 mg)
Study: 30715637
Drug: GaAlAs laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: GaAlAs laser treatment (wavelength 830 nm, 30 mW, power density 0.84 W/cm2)
Study: 30715637
Drug: LED treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LED treatment (wavelength 850 nm, 48 mW, power density 1.05 W/cm2)
Study: 30715637
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of laser and LED therapies
Study: 30715637
Drug: Both therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapies (laser and LED)
Study: 17272969
Drug: Rivastigmine 6
Normalized name: rivastigmine 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine 6 mg treatment
Study: 15665005
Drug: Home based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home based medication review by pharmacists (two home visits within two weeks and eight weeks of discharge)
Study: 15665005
Drug: Home based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home based medication review by pharmacists
Study: 10453419
Drug: High-dose pancreatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pancreatin
Study: 10453419
Drug: Standard-dose pancreatin
Normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose pancreatin
Study: 24000709
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for community-acquired pneumonia with hypertension
Study: 24000709
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (patients with community-acquired pneumonia during treatment)
Study: 22619907
Drug: 75-mg of
Normalized name: povidone-iodine 75 MG/ML [Betagen brand of povidone-iodine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75-mg of diclofenac sodium
Study: 9629994
Drug: Mizolastine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine (10 mg o.d.) and digoxin (0.25 mg o.d.)
Study: 9629994
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and digoxin (0.25 mg o.d.)
Study: 28929343
Drug: Isomaltulose (8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isomaltulose (8% carbohydrate-electrolyte drink, 20 g h-1)
Study: 28929343
Drug: Maltodextrin (8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin (8% carbohydrate-electrolyte drink, 20 g h-1)
Study: 1449044
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (r‐hGH) (0.1 IU/kg sc twice daily)
Study: 29413685
Drug: Cisplatin 25
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 25 mg/m2 and Gemcitabine 1000 mg/m2 with Panitumumab (arm A)
Study: 29413685
Drug: Cisplatin 25
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 25 mg/m2 and Gemcitabine 1000 mg/m2 without Panitumumab (arm B)
Study: 17487649
Drug: CE/MPA 0.625/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE/MPA 0.625/2.5 mg/day
Study: 17487649
Drug: CE/MPA 0.45/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE/MPA 0.45/1.5 mg/day
Study: 17487649
Drug: CE/MPA 0.3/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE/MPA 0.3/1.5 mg/day
Study: 7033014
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of cyclopenthiazide and oxprenolol (Trasidrex)
Study: 7033014
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (previous treatment discontinued)
Study: 30447975
Drug: Lycopene-enriched ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene-enriched ice cream
Study: 30447975
Drug: Control ice
Normalized name: Camphor Ice Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control ice cream
Study: 22731246
Drug: Bevacizumab (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (1.25 mg/0.1 mL)
Study: 18997832
Drug: ATL-104 (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATL-104 (50, 100 or 150 mg)
Study: 17284732
Drug: Unilateral lower
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral lower limb suspension for 4 weeks
Study: 12362963
Drug: 4 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 sessions of acceptance and commitment therapy (ACT) plus treatment as usual (TAU)
Study: 9838238
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue (2 ml applied to the axillary dissection area)
Study: 2650723
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (cisplatinum, bleomycin, vindesine, mitomycin C)
Study: 17978324
Drug: In-patient psychiatric
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-patient psychiatric treatment
Study: 17978324
Drug: General out-patient
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: General out-patient treatment
Study: 12790762
Drug: Dosulepine (TCA)
Normalized name: dosulepin
DrugBank: Dosulepin (DB09167)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosulepine (TCA) at doses of 50-250 mg
Study: 12790762
Drug: Citalopram (SSRI)
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram (SSRI) at doses of 20-80 mg
Study: 12790762
Drug: Lithium (Li)
DrugBank: Lithium succinate (DB14508)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (Li) with plasma levels of 0.66±0.08 meq/l
Study: 11124358
Drug: Medical abortion
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical abortion with methotrexate 50 mg orally followed by misoprostol 800 microg vaginally
Study: 9614721
Drug: Intrapleural instillation
Normalized name: Talc Powder for intrapleural instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural instillation of low-dose streptokinase
Study: 2877571
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg famotidine at bedtime
Study: 2656335
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg famotidine at bedtime
Study: 21990397
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + placebo
Study: 27064031
Drug: Zhuanggu joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhuanggu joint capsules combined with celecoxib capsules
Study: 27064031
Drug: Zhuanggu joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhuanggu joint capsules alone
Study: 27064031
Drug: Celecoxib capsules
Normalized name: Celecoxib Capsules
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib capsules combined with Zhuanggu joint capsule simulants
Study: 22186881
Drug: 16 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 sessions of hope‐based substance abuse treatment
Study: 22186881
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list for another term of treatment
Study: 20232582
Drug: copper zinc
Normalized name: copper gluconate / zinc picolinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: copper zinc malonate lotion plus 4% hydroquinone cream (twice daily) and tretinoin cream (once daily)
Study: 18466615
Drug: Etoricoxib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib (all doses combined)
Study: 2601834
Drug: Permanent subdural
Normalized name: penicillin G benzathine Prefilled Syringe [Permapen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permanent subdural drain with subcutaneous reservoir
Study: 29058477
Drug: Injection technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection technique (IT) education with 4-mm pen needle; intensive education and reinforcement for 6 months.
Study: 26466482
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 9 U rhGH every night for 7 days
Study: 21841050
Drug: Intravenous parecoxib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous parecoxib, 40 mg i.v.
Study: 9393568
Drug: Palliative coeliac
Normalized name: Various pain palliation radiopharmaceuticals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative coeliac axis intra-arterial cyclic infusions (CAI) consisting of mitoxantrone 10 mg/m2 on day 1, folinic acid 170 mg/m2 and 5-FU 600 mg/m2 during days 2-4, and cis-platinum 60 mg/m2 on day 5 for up to 11 cycles.
Study: 9393568
Drug: Adjuvant coeliac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant coeliac axis intra-arterial cyclic infusions (CAI) consisting of mitoxantrone 10 mg/m2 on day 1, folinic acid 170 mg/m2 and 5-FU 600 mg/m2 during days 2-4, and cis-platinum 60 mg/m2 on day 5 for up to 6 cycles.
Study: 8322238
Drug: Inhaled methacholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled methacholine with dosimeter method (maximal dose 210 mumol)
Study: 8322238
Drug: Inhaled methacholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled methacholine with tidal breathing method (730 mumol)
Study: 2825567
Drug: Beclomethasone aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone aerosol (1 mg bid)
Study: 2825567
Drug: Slow-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release theophylline (6.5 mg/kg bid)
Study: 2825567
Drug: Slow-release verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release verapamil (120 mg bid)
Study: 2825567
Drug: Cromolyn (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromolyn (20 mg qid via spinhaler)
Study: 28449627
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg lornoxicam
Study: 28449627
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg lornoxicam
Study: 28449627
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (10 ml isotonic 0.9% NaCl solution)